drugset / Trial / NCT00418262

Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD

NCT00418262

Phase 3 Completed 27 enrolled University of Oklahoma Mark L. Wolraich · collab
NaSingle-groupOpen-labelTreatment

Summary

Determine if atomoxetine is safe and well tolerated by children with fetal alcohol syndrome.

Timeline

Start
2005-08
Primary completion
2015-04-22
Completion
2015-04-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified 0.25 mg/kg Oral
Subject Atomoxetine Other / unclassified 0.5 mg/kg Oral
Subject Atomoxetine Other / unclassified 1 mg/kg Oral
Subject Atomoxetine Other / unclassified 1.4 mg/kg Oral